INDICATORS OF CENTRAL CARDIOHEMODYNAMICS IN PATIENTS WITH ARTERIAL HYPERTENSION WITH POSTINFARCTION CARDIOSCLEROSIS AND DIABETES MELLITUS TYPE 2

InterConf ◽  
2021 ◽  
pp. 161-167
Author(s):  
Inna Dunaieva ◽  
Leonid Vasyliev ◽  
Aleksandr Kozakov ◽  
Nonna Kravchun
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Arterial Hypertension ◽  
Cardiovascular Complications ◽  
Left Ventricular Diastolic Dysfunction ◽  
Left Ventricular ◽  
Postinfarction Cardiosclerosis ◽  
Central Hemodynamic ◽  
Complex Structural

Central hemodynamic parameters in 40 patients with arterial hypertension, postinfarction cardiosclerosis and type 2 diabetes were evaluated. Based on the study, it is proved that type 2 diabetes mellitus is a predictor of concentric LV myocardial hypertrophy, which can be considered as a reaction of the heart to prolonged increased load and disruption of myocardial microcirculation, contributes to complex structural and functional reorganization of the heart with a tendency to reduce myocardial contractility. Comorbidity of hypertension, postinfarction cardiosclerosis and type 2 diabetes increases the incidence of signs of left ventricular diastolic dysfunction type 1 (type of relaxation disorder), which leads to a worsening of the prognosis of cardiovascular complications.

scholarly journals Echocardiographic evaluation of left ventricular diastolic dysfunction in recently diagnosed type 2 diabetes mellitus

2018 ◽  
Vol 6 (5) ◽  
pp. 1691
Author(s):  
Swapnil Jain ◽  
C. L. Nawal ◽  
Amandeep Singh ◽  
Radhey Shyam Chejara ◽  
Sagar Barasara ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diastolic Dysfunction ◽  
Left Ventricular Diastolic Dysfunction ◽  
Left Ventricular ◽  
P Value ◽  
Diabetic Patients ◽  
Ventricular Diastolic Dysfunction

Background: Diastolic dysfunction in patients suffering from diabetes mellitus represents an earlier stage in the natural history of cardiomyopathy. This study was done to assess the left ventricular diastolic dysfunction in recently diagnosed (<5yr) Type 2 Diabetes Mellitus by Echocardiography and also to determine association of glycemic status (by HBA1c levels) with left ventricular diastolic dysfunction (LVDD).Methods: An observational descriptive study involving 100 diabetic patients, taken on first come first serve basis after applying inclusion and exclusion criteria. In all the subjects, other than routine investigations, HbA1c was estimated and echocardiography was done to evaluate LVDD.Results: Mean value of HbA1c in the study was 8.31+ 1.408 %. 63 out of 100 subjects had LVDD. There was significant positive correlation between HbA1c and LVDD (p value <0.001). As HbA1c increased, severity of LVDD increased. In this study, as BMI increased, HbA1c and LVDD increased & both findings were statistically significant (p value =0.001).Conclusion: Our study indicates that myocardial damage in patients with diabetes affects diastolic function before systolic function &higher HbA1C level is strongly associated with presence of LVDD. Patients should be advised strict control of diabetes in order to reduce the risk for developing LVDD which is a precursor for more advanced disease.Keywords: Diabetes mellitus, Diastolic dysfunction, BMI, HbA1c

scholarly journals Markers of cardiovascular complications in patients with type 2 diabetes mellitus and arterial hypertension

2018 ◽  
Vol 17 (2) ◽  
pp. 319-322
Author(s):  
Nadiia Demikhova ◽  
Olga Chernatska ◽  
Tetiana Mazur ◽  
Svetlana Bokova ◽  
Tetiana Rudenko ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Arterial Hypertension ◽  
Glycated Hemoglobin ◽  
Excretion Rate ◽  
Albumin Excretion Rate ◽  
Cardiovascular Complications ◽  
Albumin Excretion

Background: Hypertensive patients with type 2 diabetes mellitus are also at increased risk for diabetes mellitus–specific complications, including nephropathy. Even the smallest degree of albuminuria increases risk for cardiovascular diseases and all-cause death. The common conditions coexisting with type 2 diabetes (e.g., hypertension and dyslipidemia) are clear risk factors for cardiovascular diseases.Methods and materials: The first (I) group consists of 99 obtained patients with type 2 and AH, the second (II) includes 49 practically healthy people. We evaluated such markers of cardiovascular complications as glycated hemoglobin, lipid profile components by biochemical method and albumin excretion rate with the help of enzyme immunoassay.Result: The positive correlation between the level of albumin excretion rate and glycated hemoglobin (r = 0,23, p < 0,001) is confirmed that albuminuria is a main marker of diabetic nephropathy. The positive correlation between albuminuria and low density lipoproteins (r = 0,34, p < 0,001), triglycerides (r = 0,04, p < 0,001) is the definition of the important role of dyslipidemia in diabetic nephropathy.Conclusion: Determination of albumin excretion rate, glycated hemoglobin as markers of nephropathy, lipid profile components is necessary for patients with type 2 diabetes mellitus and arterial hypertension for prevention cardiovascular complications.Bangladesh Journal of Medical Science Vol.17(2) 2018 p.319-322

scholarly journals Effectiveness of atorvastatin therapy in patients with arterial hypertension, diabetic nephropathy and diabetes mellitus type 2

2019 ◽  
pp. 105-110
Author(s):  
O. M. Chernatska ◽  
T. S. Mazur ◽  
N. V. Demikhova ◽  
O. M. Vlasenko ◽  
T. M. Rudenko ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Nephropathy ◽  
Arterial Hypertension ◽  
Lipid Profile ◽  
Cardiovascular Complications ◽  
Actual Problem ◽  
Type 2 Dm

The actual problem of internal medicine is the managemen of patients with comorbid pathology. Arterial hypertension (AH) is determined in about quarter of the population in the world. Moreover, the coexistence of AH and type 2 diabetes mellitus (DM) connected with the increased risk of cardiovascular complications (CVC) compared with patients with AH. In principle dyslipidemia is the common link between AH and type 2 DM, which need the correction. No doubt that reduction of atherogenic and increase of anti atherogenic lipoproteins is necessary for persons with comorbid pathology. The objective of our study was the assessment of atorvastatin treatment in patients with AH, diabetic nephropathy and type 2 DM. We obtained 96 patients with AH, diabetic nephropathy and type 2 DM (І group), 25 persons with AH (ІІ group), 15 conditionally healthy individuals. Persons had CVC in the past. For patients from the І and ІІ group CVC were defined accordingly (4,97 ± 0,20) years and (4,10 ± 0,05) years ago (P = 0,0291). The duration of AH is (8,1 ± 0,2) years for the І group and (8,90 ± 0,13) years for the ІІ group. The levels of lipid profile spectrum were determined according to the methods of W. T. Friedewald. The results of investigation were analyzed with the help of Microsoft Excel 2016. Correction of lipid profile spectrum is the important part of multipurpose treatment for persons with coexistent pathology. All patients were treated by atorvastatin (10−40 mg/day) during 6 months in a complex therapy. The target levels of general cholesterol during 6 months were presented in 30 persons (31.91 %), low density lipoproteids – in 10 persons (10.64 %), high density lipoproteids – in 26 persons (27.66 %), triglycerides – in 34 persons (36.17 %) among patients with AH, diabetic nephropathy and type 2 DM. In conclusion, it is advisable to prescribe atorvastatin (10–40 mg/day) for correction of dyslipidemia, reduction of proatherogenic orientation, prevention of atherosclerotic process manifestation and cardiovascular complications in patients with AH with diabetic nephropathy and type 2 diabetes mellitus.

Sign in / Sign up

Export Citation Format

Share Document